Lung cancer patients with synchronous colon cancer

Kurishima, Koich; Miyazaki, Kunihiko; Watanabe, Hiroko; Shiozawa, Toshihiro; Ishikawa, Hiroichi; Satoh, Hiroaki; Hizawa, Nobuyuki

doi:10.3892/mco.2017.1471

Cited by 23 publications

(21 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In other reports of double primary lung cancers, adenocarcinoma and bronchial carcinoid tumors are considered very rare with an incidence of less than 1% and a maximum incidence rate of 16% [ 11 ]. In the literature review, most reported cases of double primary tumors of the lung and colon are either single lung neoplasms with single colon neoplasms [ 3 , 4 , 12 ] or double lung primary neoplasms [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Synchronous Double Lung Primary Malignancies and Colon Cancer

Alghanmi¹

2022

Cureus

View full text Add to dashboard Cite

We report a rare case of multiple primary malignancies, double primary lung cancers, and synchronous colon cancer. Double primary lung cancers were synchronous with adenocarcinoma of the sigmoid (carcinoid tumor and adenocarcinoma). The patient subsequently underwent two surgeries, for lung and colon cancer, followed by four cycles of carboplatin and pemetrexed treatment for the lung adenocarcinoma, with an uneventful chemotherapy course. The patient has been followed up closely for the last 18 months via CT scans and tumor marker tests and has shown no evidence of recurrence or metastasis.

show abstract

Section: Discussionmentioning

confidence: 99%

Successful Treatment of Synchronous Double Lung Primary Malignancies and Colon Cancer

Alghanmi¹

2022

Cureus

View full text Add to dashboard Cite

show abstract

“…KRAS has been labeled “undruggable” due to its comparatively smooth protein structure, encouraging scientists to focus on downstream inhibitors to target it. Fortunately, direct-targeting techniques (such as sotorasib) can now be used to limit or prevent KRAS overexpression; however, nothing is known about primary or acquired resistance to such a strategy [ 30 ].…”

Section: Discussionmentioning

confidence: 99%

KRAS G12C-Mutant Non-Small-Cell Lung Adenocarcinoma: First Documented Report in the Arabian Gulf

Alsulaiman¹,

Alharthi²,

Albariqi³

et al. 2022

Cureus

View full text Add to dashboard Cite

We report the first documented case series of two lung adenocarcinoma patients demonstrating Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations by reverse transcription-polymerase chain reaction techniques from Saudi Arabia. Both patients were males aged 64 and 76 years. The first had a heavy smoking history, while the second did not report any history of smoking. The tumor subtype was identified to be non-mucinous lung adenocarcinoma in both cases. The younger patient presented with generalized lymphadenopathy and a right-sided lung mass lesion, while the older patient exhibited stage III-A left lung adenocarcinoma that required rapid response. An initial examination of the first case showed a right-sided mediastinal shift, bilateral neck lymphadenopathy, and poorly differentiated neoplasm from a right supraclavicular core biopsy, leading to treatment with palliatives along with regular checkups. The second case was afebrile after being confirmed to be vitally stable and laboratory testing (Neutr 100). Further studies, specifically on large numbers of patients from the Arabian Gulf, are needed to confirm significant differences between the national and international populations. Additionally, future studies should investigate more differences in the differentiation of KRAS-mutant lung adenocarcinoma between patients from the Arabian Gulf and others.

show abstract

“…Chitin, as an appropriate carrier, can be used to deliver AgNP in addition to its anti-cancer properties by inhibiting anti-apoptotic genes [ 58 ]. Chitin and chitosan, as safe biological sources, can both be effective in treating cancer by drug delivery and have been shown to have anti-proliferative effects in some human cancers, including colon and lung cancers, which are two of the most common cancers in the world [ 59 , 60 , 61 ]. Colon cancer is the third most common cancer in the American population, and chemotherapy, known as a promising therapy, faces problems such as increased resistance to chemotherapy drugs [ 62 ].…”

Section: Application Of Chitin and Chitosan In Cancer Therapymentioning

confidence: 99%

Chitin and Chitosan: Prospective Biomedical Applications in Drug Delivery, Cancer Treatment, and Wound Healing

2022

View full text Add to dashboard Cite

Chitin and its derivative chitosan are highly abundant polymers in nature, appearing in both the shells and exoskeletons of various marine and non-marine species. Since they possess favorable properties, such as biocompatibility, biodegradability, non-toxicity, and non-immunogenicity, they have gained recent attention due to their enormous potential biomedical applications. The polycationic surface of chitosan enables it to form hydrogenic and ionic bonds with drug molecules, which is one of its most useful properties. Because chitosan is biocompatible, it can therefore be used in drug delivery systems. The development of chitosan-based nanoparticles has also contributed to the significance of chitin as a drug delivery system that can deliver drugs topically. Furthermore, chitin can be used in cancer treatment as a vehicle for delivering cancer drugs to a specific site and has an antiproliferative effect by reducing the viability of cells. Finally, chitosan can be used as a wound dressing in order to promote the faster regeneration of skin epithelial cells and collagen production by fibroblasts. As discussed in this review, chitin and chitosan have diverse applications in the medical field. Recognizing the biomedical applications of these two polymers is essential for future research in tissue engineering and nanobiotechnology.

show abstract

Lung cancer patients with synchronous colon cancer

Cited by 23 publications

References 14 publications

Successful Treatment of Synchronous Double Lung Primary Malignancies and Colon Cancer

Successful Treatment of Synchronous Double Lung Primary Malignancies and Colon Cancer

KRAS G12C-Mutant Non-Small-Cell Lung Adenocarcinoma: First Documented Report in the Arabian Gulf

Chitin and Chitosan: Prospective Biomedical Applications in Drug Delivery, Cancer Treatment, and Wound Healing

Contact Info

Product

Resources

About